

AMENDMENTS

In the Claims:

Please amend paragraph [0007] as indicated below. The paragraph is marked with a ~~strike through~~ to designate deletions and underlining to designate additions.

[0007] Several commercial forms of Factor VIII concentrates are available to provide replacement therapy for patients suffering from hemophilia A. For example, blood-derived Factor VIII concentrate products sold under the ~~Hemofil[®]-M~~ HEMOFIL[®] M (Baxter, Deerfield, IL), ~~Koate[®]-DVI~~ KOATE[®]-DVI (Bayer, Research Triangle Park, NC), ~~Monarc-MTM~~ MONARC-MTM (American Red Cross, Washington, D.C.), and ~~Monoclalte-P[®]~~ MONOCLATE-P[®] (Aventis, Bridgewater, NJ) brands. With respect to recombinantly prepared Factor VIII concentrates, commercial products are provided under the ~~Helixate[®]-FS~~ HELIXATE[®] FS (Aventis, Bridgewater, NJ), ~~Kogenate-FS[®]~~ KOGENATE FS[®] (Bayer, Research Triangle Park, NC), ~~Recombinate[®]~~ RECOMBINATE[®] (Baxter, Deerfield, IL), ~~Advate[®]~~ ADVATE[®] (Baxter, Deerfield, IL), and ~~ReFacto[®]~~ REFACTO[®] (Wyeth/Genetics Institute, Cambridge, MA) brands.